title: Cholesteryl ester transfer protein: pharmacological inhibition for the modulation of plasma cholesterol levels and promising target for the prevention of atherosclerosis.
abstract: Cholesteryl ester transfer protein (CETP) facilitates the exchange of neutral lipids (such as cholesteryl esters and triglycerides) between anti-atherogenic HDL particles and pro-atherogenic VLDL and LDL particles in human plasma. Individuals possessing a genetic deficiency for CETP have higher HDL cholesterol and lower LDL cholesterol and may have a reduced risk for developing cardiovascular disease. Small molecule inhibitors of CETP are being developed that would appear to provide a beneficial change in lipoprotein profile. However, randomized clinical trials are ultimately required to determine whether CETP inhibition will afford a reduction in cardiovascular events.
authors.affiliation: Department of Medicinal Chemistry, Cardiovascular and Metabolic Diseases, Pfizer Global Research and Development, Groton, CT 06340, USA. roger_b_ruggeri@groton.pfizer.com
authors.forename: Roger B
authors.initials: RB
authors.lastname: Ruggeri
mesh_terms: D001161:Arteriosclerosis / Q000097:blood* / Q000378:metabolism / Q000517:prevention & control; D002318:Cardiovascular Diseases / Q000517:prevention & control; D002352:Carrier Proteins / Q000187:drug effects / Q000378:metabolism*; D002784:Cholesterol / Q000097:blood* / Q000378:metabolism; D053480:Cholesterol Ester Transfer Proteins; D016503:Drug Delivery Systems; D006023:Glycoproteins / Q000172:deficiency / Q000187:drug effects / Q000378:metabolism*; D006801:Humans; D000960:Hypolipidemic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D008074:Lipoproteins / Q000097:blood / Q000378:metabolism; D016032:Randomized Controlled Trials as Topic
chemical_list: C506642:CETP protein, human; D002352:Carrier Proteins; D053480:Cholesterol Ester Transfer Proteins; D006023:Glycoproteins; D000960:Hypolipidemic Agents; D008074:Lipoproteins; D002784:Cholesterol